Sodium, blood pressure and cardiovascular pathology: is it all volaemia?

Vanrenterghem Y. A prospective placebo-controlled randomised single centre study of mycophenolate mofetil treatment for IgA nephropathy: lack of clinical efficacy after two years. J Am Soc Nephrol 2001; 12: 114 26. Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 1991; 36: 60–66 27. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34: 103–107 28. Furuta T, Hotta O, Horigome I et al. Steroid pulse therapy combined with tonsillectomy in IgA nephropathy associated with diabetes mellitus. Nephron 2001; 89: 398–401 29. Hotta O, Furuta T, Chiba S. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 2002; 39: 493–502 30. Xie Y, Nishi Y, Ueno M et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861–1867 31. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomised and controlled trial. J Am Soc Nephrol 2003; 14: 1578–1583 32. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361; 117–124 33. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8: 1739–1744 34. Hogg RJ, Lee J Nordelli NA, Cattren D, Hurschma G, Juliun BA. Multicentre placebo – controlled trial of alternate-day predrisone or daily omega-3 fatty acids in children and young adults with IgA nephropathy. J Am Soc Nephrol 2003; 14: 751A 35. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant 2003: 18: 241–245 36. Ballardie FW. Systemic Lupus and Other Connective Tissue Disease Nephropathies. In Nephrology 1997. Ch51; 306–421. Ed. R Wilkinson and R Jamison, pub. Chapman and Hall, London 37. Kelley VR, Wuthrich RP. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin Nephrol 1999; 19: 57–66 38. deCaestecker M, Bottomley M, Telfer BA, Hutchinson IVH, Vose BM, Ballardie FW. Detection of abnormal cytokine networks in human IgA nephropathy. Kidney Int. 1993; 44: 1298–1308 39. Bakris G, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661 40. Peterson JC, Adler S, Burkart JM et al., Modification of Diet in Renal Disease Study Group. Blood pressure control, proteinuria, and the progression of renal disease. Ann Int Med 1995; 123: 754–762